Hodgkin lymphoma and ADCETRIS
ADCETRIS is injected intravenously and has been approved by the FDA in three indications: for the treatment of Hodgkin lymphoma after failure of autologous hematopoietic stem cell transplantation (auto-HSCT) or after the failure of two prior multi-agent chemotherapy treatments, for treatment of HL patients at high risk of relapse or progression as post-auto-HSCT and for the treatment of patients with systemic anaplastic large cell lymphoma (sALCL) after the failure of prior multi-agent chemotherapy treatment. Health Canada approved ADCETRIS in 2013 for relapsed or refractory HL and sALCL and for post-ASCT treatment for JL patients with an increased risk of advancement or relapse.
The European Commission granted ADCETRIS authorization in October 2012 for two indications. First, for the treatment of HL CD30-positive patients following autologous stem cell transplants (ASCT) or after two previous treatments when ASCT or a multi-agent chemotherapy was not an option. And second, for the treatment of patients with relapsing or refractory sALCL.
ADCETRIS has been approved in 67 countries for relapsing or refractory HL and sALCL.